1800-272-662
Shopping Cart 0
countryflagAU
Login

Willow Biosciences Inc

Healthcare CA WLLW

NoneCAD
-(-%)

Last update at 2025-09-25T20:00:14.015103Z

Day Range

--
LowHigh

52 Week Range

0.030.72
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap5.15M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.92000M
  • Revenue TTM6.37M
  • Revenue Per Share TTM0.23
  • Gross Profit TTM 1.31M
  • Diluted EPS TTM-0.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.76100M -6.14000M -33.94600M -46.14696M -
Minority interest - - - - -
Net income -14.81400M 10.51M -51.16100M -44.56659M -
Selling general administrative 8.29M 7.79M 6.42M 8.24M -
Selling and marketing expenses 0.81M 0.82M - - -
Gross profit 0.82M 0.13M 0.01000M 0.00458M -
Reconciled depreciation 2.65M 3.19M 3.18M 2.17M -
Ebit -18.39300M -23.33000M -23.06100M -46.14696M -1.64456M
Ebitda -15.45400M -19.56800M -13.50900M -10.79568M -
Depreciation and amortization 2.94M 3.76M 9.55M 35.35M -
Non operating income net other - - - - -
Operating income -18.39300M -23.33000M -23.06100M -46.14696M -
Other operating expenses 19.22M 23.31M 16.86M 13.08M -
Interest expense 0.03M 0.03M 0.04M 0.05M 0.00000M
Tax provision 0.05M - 0.00000M -1.58037M -
Interest income 0.30M 0.41M 0.15M 0.06M -
Net interest income 0.27M 0.39M 0.12M 0.06M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M -16.64700M 17.21M -1.58037M -
Total revenue 0.82M 0.13M 0.01000M 0.00458M -
Total operating expenses 19.22M 23.31M 16.86M 13.08M -
Cost of revenue - - - - -
Total other income expense net 3.63M 17.19M -10.88500M -33.13498M -
Discontinued operations - - - - -
Net income from continuing ops -14.81400M -6.14000M -33.94600M -44.56659M -
Net income applicable to common shares -14.81400M -6.14000M -33.94600M -44.56600M -1.64456M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.49M 6.67M 18.15M 35.02M 21.86M
Intangible assets - 0.00500M - - 0.00000M
Earning assets - - - - -
Other current assets - 0.62M 0.64M 0.73M 0.56M
Total liab 2.99M 3.24M 1.77M 5.33M 22.42M
Total stockholder equity -0.50500M 3.44M 16.37M 29.68M -0.55900M
Deferred long term liab - - - - -
Other current liab - 0.32M 1.09M 0.76M 0.98M
Common stock - 118.18M 118.07M 118.03M 83.17M
Capital stock 120.89M 118.18M 118.07M 118.03M 83.17M
Retained earnings -127.87400M -121.68500M -108.65600M -93.84200M -87.70200M
Other liab - - 0.02M 3.77M 20.58M
Good will - - - - -
Other assets - - 0.00000M 0.10M 0.09M
Cash 0.33M 3.15M 11.01M 30.12M 15.89M
Cash and equivalents - - 11.01M 30.12M 15.89M
Total current liabilities 1.99M 1.81M 1.72M 1.41M 1.56M
Current deferred revenue - 0.13M - 0.01000M -
Net debt 0.38M -0.98900M -10.34300M -29.31700M -15.02600M
Short term debt - 0.73M 0.63M 0.64M 0.59M
Short long term debt - 0.08M - - -
Short long term debt total - 2.16M 0.66M 0.80M 0.87M
Other stockholder equity - 7.31M 7.32M 5.91M 4.29M
Property plant equipment - - 1.92M 3.60M 4.67M
Total current assets 0.66M 4.17M 16.23M 31.27M 17.03M
Long term investments - - - - -
Net tangible assets - - - 29.63M -0.62400M
Short term investments 0.02M 0.02M 4.02M - 0.00000M
Net receivables 0.04M 0.17M 0.28M 0.09M 0.29M
Long term debt 0.71M 0.59M - - -
Inventory 0.06M 0.22M 0.28M 0.38M 0.29M
Accounts payable - 0.64M 1.09M 0.76M 0.98M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.36900M -0.36500M -0.41000M -0.31500M
Additional paid in capital - - - - -
Common stock total equity - - - - 83.17M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.06M - 0.10M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 1.83M 2.50M 1.92M 3.75M 4.83M
Capital lease obligations 1.26M 1.48M 0.66M 0.80M 0.87M
Long term debt total - - 0.03M 0.16M 0.28M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.55300M -1.67400M -0.83700M -6.83099M -
Change to liabilities 0.00000M 0.00000M 0.00000M 0.00000M 0.04M
Total cashflows from investing activities -4.55300M -1.67400M -0.83700M -6.83100M -0.20284M
Net borrowings -0.72300M -0.63700M -0.65100M -0.49300M -0.02106M
Total cash from financing activities -0.72300M 34.13M 9.89M 35.26M 1.32M
Change to operating activities 0.13M -0.31600M -0.21100M -0.35200M -0.04042M
Net income -14.81400M -6.14000M -33.94600M -44.56659M -1.64456M
Change in cash -19.11200M 14.22M -3.74900M 19.27M -0.21617M
Begin period cash flow 30.12M 15.89M 19.64M 0.37M 0.09M
End period cash flow 11.01M 30.12M 15.89M 19.64M 0.37M
Total cash from operating activities -13.86200M -18.22700M -12.78000M -9.16140M -1.33308M
Issuance of capital stock 0.00000M 26.73M 10.52M 27.38M -
Depreciation 2.65M 3.19M 3.18M 2.17M 0.05M
Other cashflows from investing activities -3.87100M -0.02700M -0.00500M -0.17700M -0.17700M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -0.32661M
Sale purchase of stock 0.00000M 34.77M 10.52M 35.87M -
Other cashflows from financing activities -4.55300M 8.03M 0.03M 8.38M -0.01108M
Change to netincome -1.82300M -14.96300M 18.20M 33.59M 0.59M
Capital expenditures 0.68M 1.77M 1.00M 6.71M 0.20M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.13M -0.31600M -0.21100M -0.35105M -
Stock based compensation 1.46M 1.70M 0.95M 2.59M -
Other non cash items -3.28400M -16.66600M 17.24M 32.58M -
Free cash flow -14.54400M -19.99300M -13.77700M -15.87382M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
WLLW
Willow Biosciences Inc		 - -% - - 67.57 0.81 9.89 1.54 -332.4957
BHC
Bausch Health Companies Inc		 0.08 1.10% 7.33 5.94 1.34 0.29 18.74 2.18 6.64
CURA
Curaleaf Holdings Inc.		 0.02 0.65% 3.08 - 138.89 1.90 2.05 1.88 11.75
CRON
Cronos Group Inc		 0.01 0.29% 3.44 23.40 32.26 10.16 0.92 1.27 -1.9458
TLRY
Tilray Inc		 -0.14 1.40% 9.83 - 1000.00 1.34 0.56 1.09 -2.299

Reports Covered

Stock Research & News

View All

Profile

Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.

Willow Biosciences Inc

202, 1201-5th Street SW, Calgary, AB, Canada, T2R 0Y6

Key Executives

Name Title Year Born
Dr. Peter Seufer-Wasserthal Ph.D. Pres, CEO & Chairman 1962
Mr. Travis Doupe Chief Financial Officer 1972
Dr. Chris Savile Chief Operations Officer NA
Mr. Simon Hickling Ph.D. Sr. VP of Bus. Devel. NA
Dr. Trish Choudhary VP of R&D NA
Mr. Troy T. Talkkari VP of Corp. Devel. NA
Mr. Sanjib Singh Gill L.L.B. Corp. Sec. 1976
Mr. Travis Doupe Chief Financial Officer 1971
Dr. Chris Savile President, Director & CEO NA
Mr. Sanjib Singh Gill L.L.B. Corporate Secretary 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.